The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | ALPINE: QoL in patients with R/R CLL treated with zanubrutinib vs ibrutinib
Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Apellis Pharmaceuticals, Leeds, UK, compares the health-related quality of life (QoL) outcomes associated with zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) from the ALPINE trial (NCT03734016). The ALPINE trial showed that zanubrutinib was more tolerable than ibrutinib and led to better overall outcomes. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
